Dosing & Uses
Dosage Forms & Strengths
Acute Coronary Syndrome
Reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome (ACS) managed by means of percutaneous coronary intervention (PCI) who have either (a) unstable angina or non-ST-elevation MI (NSTEMI) or (b) ST-elevation MI (STEMI) when managed with primary or delayed PCI
60 mg PO once as loading dose, then 10 mg/day PO in combination with aspirin 81-325 mg/day; if patient <60 kg, consider 5 mg/day PO because of potentially increased bleeding risk (efficacy and safety not established)
- Dose adjustment not necessary
- Mild-to-moderate: Dose adjustment not necessary
- Severe: Not studied
Sickle Cell Disease (Orphan)
Orphan designation for treatment of sickle cell disease
- Eli Lilly; Lilly Corporate Center; Indianapolis, IN 46285
Acute Coronary Syndrome
60 mg PO once as loading dose, then 10 mg/day PO in combination with aspirin 81-325 mg/day
Weight <60 kg: consider 5 mg/day because of potentially increased bleeding risk (efficacy and safety not established)
Generally not recommended, because of increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk patients (diabetes or prior MI), for whom effect appears to be greater and use may be considered
Serious - Use Alternative
Significant - Monitor Closely
Thrombotic thrombocytopenic purpura
Abnormal hepatic function
Abnormal liver function
Black Box Warnings
Potential for significant, sometimes fatal, bleeding
- Do not use in patients with active bleeding or a history of transient ischemic attack (TIA) or stroke
- Generally not recommended for age >75 years (increased risk of fatal and intracranial bleeding and uncertain benefit, except in high-risk patients [diabetes or prior MI])
- Do not initiate in patients undergoing urgent coronary artery bypass grafting (CABG); if possible, discontinue at least 7 days before any surgical procedure
- If possible, manage bleeding without discontinuing (risk of subsequent cardiovascular events is increased if prasugrel stopped, particularly in first few weeks after ACS)
Additional risk factors for bleeding
- Weight <60 kg
- Propensity to bleed (eg, recent trauma, recent surgery, recent or recurrent GI bleeding, active peptic ulcer disease, severe hepatic impairment, or moderate-to-severe renal impairment)
- Concomitant use of other drugs that increase bleeding risk
Active pathologic bleeding (eg, peptic ulcer, intracranial hemorrhage)
Prior TIA or stroke
Hypersensitivity with angioedema reported
Thrombocytopenic purpura occurring within 2 weeks of initiation of therapy reported
Use caution in severe hepatic impairment and end-stage renal disease
Use caution in patients taking anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), or fibrinolytics
Bleeding may increase in patients <60 kg
See Black Box Warnings
Pregnancy & Lactation
Pregnancy category: B
Lactation: Not known if drug excreted in breast milk; discontinue, or do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Prasugrel is a prodrug, a thienopyridine that inhibits platelet activation and aggregation through irreversible binding of active metabolite to adenosine phosphate (ADP) platelet receptors (specifically, P2Y12 receptor)
Peak plasma time: 30 min
Protein bound: Active metabolite, 98%
Vd: 44-48 L
Rapidly hydrolyzed in intestine to active metabolite via CYP3A4 and CYP2B6
Half-life: 7 hr (range, 2-15 hr)
Clearance: 112-166 L/hr
Excretion: Urine (68%), feces (27%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs